|Soo Aleman, MD, PhD, assoc prof is working as hepatologist at department of Infectious Diseases and department of Gastroenterology and Hepatology at Karolinska University Hospital, Sweden. The main focus of her current research is to assess the risks and risk factors for hepatocellular cancer after hepatitis C treatment with sustained virological response in clinical cohort studies. She has also research collaborations about clinical and translational studies about hepatitis B/D/C nationally and internationally. She is currently the main investigator of a genomic study of hepatocellular carcinoma developed after hepatitis C cure in an international network from Europe, USA and Canada.|
|Dr. Aftab (Tab) Ansari is Professor of Pathology & Lab Medicine at Emory University School of Medicine located in Atlanta, GA, USA, a position he has held since 1985. He is an immunologist by training and has published extensively in the fields of basic cellular immunology, transplantation immunology, human autoimmune diseases and of late infectious disease immunology. The focus of his studies currently centers on defining the mechanisms of pathogenesis of human HIV infection using the SIV infected nonhuman primate model with special emphasis on the role of gut homing cells and on defining the mechanisms associated with human primary biliary cirrhosis. He is an author of > 730 peer reviewed journal articles and has held senior positions at the US National Institutes of Health, United States Naval Medical Research Laboratories in Bethesda, Maryland and overseas locations in Cairo, Egypt and Jakarta, Indonesia.|
|Silvia Bertagnolio graduated in Medicine in 1997 and in 2001 specialized in Infectious Diseases at the Catholic University of Rome. Between 2001 and 2003 she worked at the University Hospital as infectious disease phisician and since 2003 has been staff with the World Health Organization (WHO), in Geneva, Switzerland, where she is leading work on HIV Drug Resistance (HIVDR).
At WHO, she coordinates the development of global strategies on HIVDR, the design and implementation of surveillance of HIVDR in low and middle income countries; the establishment of the Global WHO Laboratory Network; and the development of guidelines on HIVDR management.
She coordinates WHO’s HIVDR prevention and response in over 50 low- and middle-income countries. Her areas of expertise are HIV drug resistance, Epidemiology, Public Health, and Infectious Diseases.
She has an academic affiliation with the University College London, UK, as Honorary Research Associate and has qualified as Associate Professor of Infectious Diseases in Italy. Silvia has been Guest Editor of several journals, including Journal of Infectious Diseases and Clinical Infectious Diseases, and has served on several grant review panels.. Silvia published over 70 peer-reviewed papers, and several book chapters.
|Francesca Chiodi is Professor in Host-Parasite Interaction. She has been the supervisor of 25 PhD students. She is the author of more than 120 publications in the field of HIV virology and immunology. Her research is translational and focuses on characterizing the molecular mechanisms leading to declined function and number of B and T cells during HIV infection. Her group has conducted extensive functional and phenotypical studies on B and T cells in HIV infected patients and the impact of early ART on the biology of these cells.|
|Paola Cinque, M.D., Ph.D. is currently working as senior physician at the Department of Infectious Diseases and responsible of the Neurovirology Research Unit at the Research Division of Immunology, Transplantation and Infectious Diseases of San Raffaele Scientific Institute, Milan, Italy, and as contract Professor of Infectious Diseases at San Raffaele University.
Her research group is mainly involved in studies on HIV Infection of the Central Nervous System, Progressive Multifocal Leukoencephalopathy and other HIV-associated CNS complications.
She is a panel member of the Italian HIV Treatment Guidelines, of the EACS Co-morbidities and of the Opportunistic Infections Guidelines, and of the NIH/CDC/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections.in HIV-Infected Adults and Adolescents.
Ann-Brit Eg Hansen
|Ann-Brit Eg Hansen is associate professor and senior consultant at Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, where she is engaged in treatment of HIV-infected patients and responsible for the treatment of patients with primary immunodeficiencies. She is also a board member of the Danish Society of Infectious Diseases. She has a PhD from the Danish HIV Cohort Study and has been involved in HIV-research since 2003 conducting both epidemiological and clinical studies. Her research interests include comorbidity in HIV-infected patients with focus on metabolic complications of antiretroviral therapy, initially with focus on lipodystrophy and in recent years with focus on bone disorders.|
|Jan Gerstoft is professor of clinical virology at the University of Copenhagen, Denmark. He works at the department of infectious diseases at Rigshospitalet where he is heading the outpatient clinic that primarily takes care of HIV and hepatitis patients. His research has mainly been focused on HIV, since he described the first European AIDS patients in 1981. His research has involved clinical trials of antiviral agents, resistance and cohort studies of co-morbidities. The research has been published in more than 400 papers often in high impact journals.|
|Judith Gottwein, MD and Dr. med. from Heidelberg University, holds a position as Associate Professor for the Experimental Control of Hepatitis C Virus (HCV) at Copenhagen Hepatitis C Program at the Department of Infectious Diseases at Copenhagen University Hospital, Hvidovre and at the Department of Immunology and Microbiology at University of Copenhagen. Her current research focus is HCV vaccine development and the study of HCV resistance to antivirals.|
|Christophe Hézode, MD, PhD, has been a hepatologist in the Department of Hepatology, Henri Mondor Hospital, University Paris-Est, Créteil, France, since 1996. He is member of the INSERM U955 group directed by Professor Jean-Michel Pawlotsky. Professor Hézode’s research experience is focused on viral hepatitis and he is the author of 148 papers published in peer-reviewed medical or scientific journals. He is the head of the French early access program for the use of first generation protease inhibitors (CUPIC cohort). He is also member of several professional societies or organisations including the French Association for the Study of the Liver (AFEF), the French National Agency for AIDS and Viral Hepatitis Research (ANRS) and the European Association for the Study of the Liver (EASL).|
|Magnus Lindh is professor in clinical virology at the University of Gothenburg and head of the virology section at Clinical Microbiology, Sahlgrenska University Hospital. His main research interest is molecular and clinical aspects on chronic hepatitis B virus infection.|
|Mala Maini is a Professor of Viral Immunology in the Division of Infection and Immunity at UCL, London, Deputy Head of Department and also works as a Consultant Physician in the viral hepatitis clinic. Her lab is at the forefront internationally of research on liver immunity and immunopathology, focusing on cellular interactions in viral hepatitis. By dissecting the immune correlates of viral persistence and liver damage they aim to contribute to the development of novel immunotherapeutic strategies for hepatitis B and hepatocellular carcinoma. Research in the Maini lab is funded by the Wellcome Trust and Medical Research Council.
For more details on the lab’s work see: http://www.ucl.ac.uk/maini-group
Carlo Federico Perno
|Carlo Federico Perno is Professor of Virology at the University of Rome Tor Vergata, Italy, and Head of Virology at the Policlinico Tor Vergata Hospital
His research is mostly dedicated to antiviral therapy, with particular emphasis to HIV infection, Hepatitis infections, and viral diseases in immunocompromised patients.
He has published about 500 papers on peer-reviewed journals.
He holds research grants from EC, the National Research Council, the Ministry of Health, and UNESCO also aimed at scientific and clinical studies on HIV infection.
|Javier Martinez-Picado is ICREA Research Professor at the AIDS Research Institute (IrsiCaixa) in Barcelona, an institution that works to advance clinical research and translate results into patients care. He is also associate professor at the University of Vic. He received his PhD from the University of Barcelona where he subsequently became associated professor lecturing on different microbiology-related subjects. In 1996, he joined the Massachusetts General Hospital as postdoctoral fellow of Harvard Medical School, where he engaged in AIDS research. In 2000, he obtained a position as biomedical researcher of the Spanish Health Department appointed to the Hospital “Germans Trias i Pujol” in Badalona (Barcelona). The research programs he is leading focus on understanding how HIV causes disease in recently infected people, exploring the best antiretroviral treatment strategies, fighting drug resistance, and collaborating on global HIV/AIDS vaccine development projects. He is currently co-chair of the IciStem Consortium and faculty of the BEAT-HIV Collaboratory. Dr. Martinez-Picado serves on different government, academic and industry advisory boards and has published extensively on HIV treatment strategies and HIV pathogenesis in international journals.|
|Dr. Bart Rijnders, MD, PhD, is associate professor in infectious diseases at the university hospital Erasmus MC in Rotterdam, the Netherlands. He studied medicine and defended his PhD on catheter-related infections at the University of Leuven in Belgium.
His research focus is on infections in the immunocompromised host that include patients with HIV and haematological disease. He has a special interest in clinical studies on the treatment of HIV and side effects of cART and on the diagnosis and treatment of sexually transmitted diseases and acute HCV in HIV positive patients. In haematology patients his research addresses the prevention, diagnosis and treatment of infections in particular invasive fungal infections and catheter-related infections.
Recently completed studies on HIV and HCV addressed issues like the assumed equivalence of FTC and 3TC, the risk of TDF renal toxicity during concomitant MRP4 inhibitor use, the efficacy of acute HCV therapy with boceprevir/peg/rbv and the safety and efficacy of a nevirapine to rilpivirine switch. Several other multicenter studies are ongoing and address issues like the efficacy of dolutegravir maintenance monotherapy in a randomized non-inferiority trial, the efficacy of 8 weeks of grazoprevir and elbasvir for acute HCV, the incidence of IRIS in patients with a CD4 <200 cells/ml that start an integrase inhibitor containing cART regimen and the safety of tenofovir- alafenamide (TAF) compared with abacavir in patients with Tenofovir disoproxil fumarate (TDF) induced renal toxicity.
Outside the context of his work, he likes to enjoy endurance sports in summer and winter, if possible in the beautiful nature of Scandinavia.
|Johan Sandberg is a Professor of Viral Immunology and Deputy Head of the Center for Infection Medicine at Karolinska Institutet. Prof. Sandberg’s research is focused on understanding the role of cellular immune responses in the context of viral infections in humans. Currently, his research is focused to a large extent on human T cell subsets with innate-like characteristics such as Mucosa-associated Invariant T (MAIT) cells and invariant Natural Killer T (iNKT) cells. His work is supported by grants from the Swedish Research Council, the US National Institutes of Health and the Swedish Cancer Society. For more detailed information please visit the group’s website: http://ki.se/en/medh/johan-sandberg-group|
|Irini Sereti is a senior investigator at the Laboratory of immunoregulation at the National Institutes of Health (NIH) in Bethesda, Maryland, USA. She does translational clinical research serving as the principal investigator in clinical protocols and her lab is conducting bench work stemming from them. Her research interests include inflammation in HIV, both as acute response to therapy initiation in persons with advanced disease and opportunistic infections (IRIS), as well as in chronic treated infection that can be associated to cardiovascular complications. She also follows a cohort of patients with idiopathic CD4 lymphopenia (ICL) and evaluates possible etiologies and potential therapeutic strategies of this rare syndrome. She enjoys mentoring students, postdocs and fellows in infectious diseases and immunology.|
|Prof. Dr. Robert Thimme is the Director of the Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases). His research focus lies on the immune responses in hepatitis B virus (HBV) and hepatitis C virus (HCV) infection as well as hepatocellular carcinoma (HCC). His main focuses are the immunological determinants of viral clearance and persistence with a special focus on CD8+ T cells. His work is supported by grants from the DFG, BMBF, several foundations and the EU. He has published more than a hundred papers on the tissue of immunobiology of HBV, HCV and HCC and is or has been in the editorial boards of several journals, such as Journal of Clinical Investigation, Gastroenterology, GUT, Journal of Hepatology, Journal of Virology or Journal of Infectious Diseases.|
|Susana Valente is currently an Associate Professor in the Department of Immunology and Microbiology at the Florida campus of The Scripps Research Institute (TSRI). Dr. Valente received a B.S. degree in Applied Chemistry/Biotechnology from the University of Lisbon, Portugal, an M.S. in Biotechnology from Montfort University, UK, and a Ph.D in Virology from the University of Paris VII-Denis Diderot in 2002. She then pursued post-doctoral studies in the laboratory of Prof. Stephen Goff at Columbia University, New York. A career development award from the National institute of Health (NIH) helped jumpstart her independent group in late 2009 at Scripps Florida. Dr. Valente’s research over the past 7 years focuses on the development of antiviral molecules and alternative approaches to HIV eradication. Dr. Valente has received numerous awards for her creative work in science, including the prestigious American Foundation for AIDS research fellowship, NIH Career Development Award and Landenberger foundation early career award. Her laboratory is currently funded with grants from NIH NIAID and Campbell Foundation.|
|Nina Weis is associate professor and senior physician at Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. She is Head of DANHEP, the Danish Database for Hepatitis B and C, with chronic viral hepatitis being the main topic of her research; both investigator initiated and in clinical trials of direct acting antiviral therapy of hepatitis C.|
|Aylin Yilmaz is a specialist in infectious diseases and a senior consultant at the Department of Infectious Diseases at Sahlgrenska University Hospital, Gothenburg, Sweden. Her research mainly focuses on HIV-infection and the central nervous system.|
|Maurizio Zazzi is professor of Microbiology at the University of Siena, Italy. He has been involved in HIV related activities since the beginning of the epidemic, sharing his time between clinical duties and research efforts. In particular, he has developed several molecular assays for monitoring the course of HIV infection with a special focus on HIV drug resistance. Together with colleagues from Sweden and Germany, he is one of the founders of the EuResist consortium, a Europe wide HIV data collection and research platform for large studies on the impact of HIV evolution on antiretroviral treatment.|